Education
About Us
Working with TipRanks
Follow Us
Ascentage Pharma Group International (HK:6855)
:6855
RESEARCH TOOLSreports
6855 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$26.05 - HK$86.70
Previous CloseN/A
Volume1.20M
Average Volume (3M)6.53M
Market Cap
HK$26.56B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding371,853,500
10 Day Avg. Volume5,241,391
30 Day Avg. Volume6,529,855
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$73.00Price Target Upside1.39% Upside
Rating ConsensusHold
Number of Analyst Covering0
Ascentage Pharma Group International News
6855 FAQ
What was Ascentage Pharma Group International’s price range in the past 12 months?
Ascentage Pharma Group International lowest stock price was HK$26.05 and its highest was HK$86.70 in the past 12 months.
What is Ascentage Pharma Group International’s market cap?
Ascentage Pharma Group International’s market cap is HK$26.56B.
When is Ascentage Pharma Group International’s upcoming earnings report date?
Ascentage Pharma Group International’s upcoming earnings report date is Aug 26, 2025 which is in 23 days.
How were Ascentage Pharma Group International’s earnings last quarter?
Ascentage Pharma Group International released its earnings results on Mar 27, 2025. The company reported -HK$2.062 earnings per share for the quarter, missing the consensus estimate of HK$0.033 by -HK$2.095.
Is Ascentage Pharma Group International overvalued?
According to Wall Street analysts Ascentage Pharma Group International’s price is currently Undervalued.
Does Ascentage Pharma Group International pay dividends?
Ascentage Pharma Group International does not currently pay dividends.
What is Ascentage Pharma Group International’s EPS estimate?
Ascentage Pharma Group International’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascentage Pharma Group International have?
Ascentage Pharma Group International has 371,853,500 shares outstanding.
What happened to Ascentage Pharma Group International’s price movement after its last earnings report?
Ascentage Pharma Group International reported an EPS of -HK$2.062 in its last earnings report, missing expectations of HK$0.033. Following the earnings report the stock price went up 8.832%.
Which hedge fund is a major shareholder of Ascentage Pharma Group International?
Currently, no hedge funds are holding shares in HK:6855
Ascentage Pharma Group International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$73.00 (1.39% Upside)
HK$73.00 (1.39% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.66%
12-Months-Change
Fundamentals
Return on Equity
-253.12%
Trailing 12-Months
Asset Growth
1.46%
Trailing 12-Months
Company Description
Ascentage Pharma Group International
Ascentage Pharma Group International (6855) is a global clinical-stage biopharmaceutical company focused on developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. The company's core products include small-molecule drugs that target key protein-protein interactions to restore apoptosis, a natural process of programmed cell death that is often dysregulated in cancer cells. Ascentage Pharma operates primarily in the biotechnology sector, leveraging its expertise in drug discovery and development to address unmet medical needs.
Technical Analysis
Shanghai Henlius Biotech, Inc. Class H
―
Everest Medicines Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
InnoCare Pharma Ltd.
―
Ownership Overview
―
Insiders
2.22%
Mutual Funds
― Other Institutional Investors
94.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---